Explore European Union Legislation by Asking a Legal Question
assisted-checkbox
filter-instruction-1
positive-filters
negative-filters
act-filter tabs-all
parameters-title
query
assisted-checkbox: ✅
result-title
total 2
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance) article annex_III CELEX: 02007R1394-20190726 Labelling of outer/immediate packaging referred to in Article 11
(a) The name of the medicinal product and, if appropriate, an indication of whether it is intended for babies, children or adults; the international non-proprietary name (INN) shall be included, or, if the product has no INN, the common name; (b) A description of the active substance(s) expressed qualitatively and quantitatively, including, where the product contains cells or tissues, the statement ‘This product contains cells of human/animal [as appropriate{] origin’ together with a short description of these cells or tissues and of their specific origin, including the species of animal in cases of non-human origin; (c) The pharmaceutical form and, if applicable, the contents by weight, by volume or by number of doses of the product; (d) A list of excipients, including preservative systems; (e) The method of use, application, administration or implantation and, if necessary, the route of administration. If applicable, space shall be provided for the prescribed dose to be indicated; (f) A special warning that the medicinal product must be stored out of the reach and sight of children; |
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance) article annex_III CELEX: 02007R1394-20190726 (g) Any special warning necessary for the particular medicinal product; (h) The expiry date in clear terms (month and year; and day if applicable); (i) Special storage precautions, if any; (j) Specific precautions relating to the disposal of unused medicinal products or waste derived from medicinal products, where appropriate, as well as reference to any appropriate collection system in place; (k) The name and address of the marketing authorisation holder and, where applicable, the name of the representative appointed by the holder to represent him; (l) Marketing authorisation number(s); (m) The manufacturer’s batch number and the unique donation and product codes referred to in Article 8(2) of Directive 2004/23/EC; (n) In the case of advanced therapy medicinal products for autologous use, the unique patient identifier and the statement ‘For autologous use only’. |